SCHEMBL31104140

SCHEMBL31104140

C[Si](C)(C)CCOCn1ncc(C#CCO)c(Cl)c1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.35
▸ ALDH1A1 P00352 5/20 0.35
▸ HTT P42858 5/20 0.35
▸ LMNA P02545 4/20 0.35
▸ RAB9A P51151 4/20 0.35
▸ S1PR2 O95136 3/20 0.35
▸ NPSR1 Q6W5P4 3/20 0.35
▸ MAPT P10636 3/20 0.35
▸ JAK2 O60674 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ HCRTR1 O43613 1/20 0.34
▸ S1PR4 O95977 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ HSP90AA1 P07900 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21521058 0.79 HTT (0.49) NPC1ALDH1A1HTTLMNARAB9A
SCHEMBL31104326 0.77 ALDH1A1 (0.36) NPC1ALDH1A1HTTLMNARAB9A
SCHEMBL31104413 0.76 HTT (0.36) NPC1ALDH1A1HTTLMNARAB9A
SCHEMBL31104092 0.75 ALDH1A1 (0.35) NPC1ALDH1A1HTTLMNARAB9A
SCHEMBL21522414 0.73 KAT2B (0.40) NPC1ALDH1A1HTTLMNARAB9A
SCHEMBL21522415 0.73 KAT2B (0.40) NPC1ALDH1A1HTTLMNARAB9A
SCHEMBL25075159 0.72 ALDH1A1 (0.40) NPC1ALDH1A1HTTLMNARAB9A
SCHEMBL31103949 0.71 ALDH1A1 (0.33) NPC1ALDH1A1HTTLMNARAB9A
SCHEMBL21519281 0.71 ALDH1A1 (0.40) NPC1ALDH1A1HTTLMNARAB9A
SCHEMBL31104205 0.71 ALDH1A1 (0.33) NPC1ALDH1A1HTTLMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 VIVIDION THERAPEUTICS, INC. 2025-02-20 — — US disclosed
WO-2024182693-A1 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER VIVIDION THERAPEUTICS, INC. (US) 2024-09-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 STAT3, JAK2, STAT1 NPC1 2306/4885ALDH1A1 2652/4885HTT 2654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback